You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Targeting endothelial arginase to treat diabetes-associated vascular dysfunction
SBC: ARGINETIX, INC. Topic: NHLBIDESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Technology for the non-invasive surveilance of post-traumatic compartment syndrome
SBC: Myolex Inc Topic: NIAMSPROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Technology Transfer of the ATLAS and ATHENA Programs
SBC: Odyssey Science Innovations, LLC Topic: NIDADESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients
SBC: Mercury Biomed LLC Topic: 300Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
TFEB Activator for Alzheimer's Disease Therapy
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIAOne in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currentlyclinically used drug abuse medications exist for treatment of addiction to opiatesalcoholand nicotinebut not cocaineThe objective of the proposed project is to test the hypothesis that the partial kappa agonist PPLcan be effective as a pharmacotherapy for treatment of cocaine abuseBecause of chronic drug induced changes in the kappa opioid receptor systemkappa receptor directed c ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
User Adaptation of AAC Device Voices
SBC: BIOSPEECH INC Topic: NIDCDDESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Vaginal Ring for Preventing Bacterial Vaginosis
SBC: REPROTECT, LLC Topic: NICHDDESCRIPTION (provided by applicant): Bacterial Vaginosis (BV) is an exceptionally common vaginal condition in which robust lactobacillus microflora in the vagina is replaced by a dense polymicrobial overgrowth. At any given time, about 1 in 3 women in the U.S. have BV; half are asymptomatic, and most women with symptomatic BV have only mild symptoms (increased discharge with a fishy smell). Despit ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health